The introduction of GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) has fundamentally changed what is clinically achievable, with patients routinely losing 15-22% of their body weight under proper medical supervision
Araj-Khodaei M, Noorbala AA, Yarani R, et al
Recently, the Wegovy pillan oral semaglutide optionwas also approved by the FDA, providing a convenient alternative for those who avoid injections
GLP-1 receptor agonists like Ozempic basically tell your stomach to slow down, which is great for blood sugar control and appetite, but leads to constipation, says Michael Bass, MD, a board-certified gastroenterologist and hepatologist and the founding medical director of Oshi Health
Statistical analysis Statistical analyses were conducted using IBM SPSS Statistics software (version 26.0, IBM, Chicago, IL, USA) and GraphPad Prism (version 8.2.1, GraphPad Software, San Diego, CA, USA) for data visualization
source for quality research peptides
